Chronic anavar results (in combination with interferon alfa-2b or peginterferon alfa-2b): in primary patients not previously treated with interferon alfa-2b or peginterferon alfa-2b; during exacerbations after a course of monotherapy with interferon alfa-2b or peginterferon alfa-2b; in patients refractory to monotherapy with interferon alfa-2b or peginterferon alfa-2b.
Hypersensitivity, pregnancy, lactation, chronic heart failure II6-III art, myocardial infarction, renal insufficiency (creatinine clearance – less than 50 ml / min), severe anemia, liver failure, decompensated cirrhosis, autoimmune diseases (including autoimmune hepatitis), not treatable thyroid disease, severe depression with suicidal intentions, children and Youth age (up to 18 years).
Women of childbearing age (pregnancy is not desirable), decompensated diabetes (with bouts of ketoacidosis); chronic obstructive pulmonary disease, pulmonary embolism, chronic heart failure, thyroid disease (including hyperthyroidism), bleeding disorders, thrombophlebitis, mielodeprescia, hemoglobinopathies (including thalassemia, sickle-cell anemia), depression, suicidal (including history), advanced age.
Dosing and Administration
Inside, with liquid squeezed water anavar results with a meal at 0.8-1.2 g per day in 2 divided doses (morning and evening). Simultaneously administered interferon alfa-2b – subcutaneously, 3 mln.ME 3 times a week or peginterferon alfa 2b – subcutaneously 1.5 mg / kg 1 time a week. In combination with interferon alpha-2b at a body weight of 75 kg dose of Ribavirin – 1 g per day (0.4 g in the morning and evening, 0.6 g);above 75 kg – 1.2 g per day (morning and 0.6 g of 0.6 g in the evening). In combination with peginterferon alfa-2b with a body weight less than 65 kg dose of Ribavirin – 0.8 g per day (0.4 g in the morning and evening, 0.4 g); 65-85 kg – 1 g per day (0.4 g in the morning and evening, 0.6 g); 85 kg (0.6 g in the morning and 0.6 g in the evening).
The duration of the treatment – 24 – 48 weeks; wherein for previously treated patients – not less than 24 weeks in patients with genotype 1 – 48 weeks. Patients refractory to monotherapy with alpha interferon and at relapse – at least 6 months to 1 year (depending on the clinical course and response to therapy).
Side effect On the part of the nervous system: headache, dizziness, weakness, malaise, insomnia, fatigue, depression, irritability, anxiety, emotional lability, nervousness, agitation, aggressive behavior, confusion; rarely – suicidal tendencies, increased smooth muscle anavar results tone, tremor, paresthesia, hyperesthesia, hypoesthesia, syncope. Since the cardiovascular system: reduction or increase in blood pressure, or bradi- tachycardia, palpitations, cardiac arrest. From the side of hematopoiesis: hemolytic anemia , leukopenia, neutropenia, granulocytopenia, thrombocytopenia; rarely – aplastic anemia. The respiratory system: dyspnea, cough, sore throat, shortness of breath, bronchitis, otitis media, sinusitis, rhinitis. From the digestive system: dry mouth, decreased appetite, nausea, vomiting, diarrhea, abdominal pain, constipation , taste perversion, pancreatitis, flatulence, stomatitis, glossitis, bleeding gums, hyperbilirubinemia. from the senses: the defeat of the lacrimal glands, conjunctivitis, blurred vision, violation / hearing loss, ringing in the ears. from the musculoskeletal system: arthralgia, myalgia. From the urogenital system: hot flashes, decreased libido, dysmenorrhea, amenorrhea, menorrhagia, prostatitis. Allergic reactions: skin rash, erythema, urticaria, pyrexia, angioedema, bronchoconstriction, anaphylaxis, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. Other: hair loss, anavar resultsconjunctivitis, alopecia, disturbance of the structure of hair, dry skin, hypothyroidism, chest pain, thirst, fungal infection, viral infection, flu-like cider, sweating, lymphadenopathy.